Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial.
Rodriguez B, Asmuth DM, Matining RM, Spritzler J, Jacobson JM, Mailliard RB, Li XD, Martinez AI, Tenorio AR, Lori F, Lisziewicz J, Yesmin S, Rinaldo CR, Pollard RB. Rodriguez B, et al. Among authors: asmuth dm. J Acquir Immune Defic Syndr. 2013 Dec 1;64(4):351-9. doi: 10.1097/QAI.0b013e3182a99590. J Acquir Immune Defic Syndr. 2013. PMID: 24169120 Free PMC article. Clinical Trial.
Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384.
Gandhi RT, Spritzler J, Chan E, Asmuth DM, Rodriguez B, Merigan TC, Hirsch MS, Shafer RW, Robbins GK, Pollard RB; ACTG 384 Team. Gandhi RT, et al. Among authors: asmuth dm. J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):426-34. doi: 10.1097/01.qai.0000226789.51992.3f. J Acquir Immune Defic Syndr. 2006. PMID: 16810109 Clinical Trial.
Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384.
Robbins GK, Spritzler JG, Chan ES, Asmuth DM, Gandhi RT, Rodriguez BA, Skowron G, Skolnik PR, Shafer RW, Pollard RB; AIDS Clinical Trials Group 384 Team. Robbins GK, et al. Among authors: asmuth dm. Clin Infect Dis. 2009 Feb 1;48(3):350-61. doi: 10.1086/595888. Clin Infect Dis. 2009. PMID: 19123865 Free PMC article. Clinical Trial.
Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects.
Skowron G, Spritzler JG, Weidler J, Robbins GK, Johnson VA, Chan ES, Asmuth DM, Gandhi RT, Lie Y, Bates M, Pollard RB; NIH/NIAID ACTG 384 Protocol Team and Monogram Biosciences. Skowron G, et al. Among authors: asmuth dm. J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):250-8. doi: 10.1097/QAI.0b013e3181938faf. J Acquir Immune Defic Syndr. 2009. PMID: 19194319 Free PMC article. Clinical Trial.
IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection.
Sereti I, Dunham RM, Spritzler J, Aga E, Proschan MA, Medvik K, Battaglia CA, Landay AL, Pahwa S, Fischl MA, Asmuth DM, Tenorio AR, Altman JD, Fox L, Moir S, Malaspina A, Morre M, Buffet R, Silvestri G, Lederman MM; ACTG 5214 Study Team. Sereti I, et al. Among authors: asmuth dm. Blood. 2009 Jun 18;113(25):6304-14. doi: 10.1182/blood-2008-10-186601. Epub 2009 Apr 20. Blood. 2009. PMID: 19380868 Free PMC article. Clinical Trial.
Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial.
Asmuth DM, Murphy RL, Rosenkranz SL, Lertora JJ, Kottilil S, Cramer Y, Chan ES, Schooley RT, Rinaldo CR, Thielman N, Li XD, Wahl SM, Shore J, Janik J, Lempicki RA, Simpson Y, Pollard RB; AIDS Clinical Trials Group A5192 Team. Asmuth DM, et al. J Infect Dis. 2010 Jun 1;201(11):1686-96. doi: 10.1086/652420. J Infect Dis. 2010. PMID: 20420510 Free PMC article. Clinical Trial.
Molecular characterization of stool microbiota in HIV-infected subjects by panbacterial and order-level 16S ribosomal DNA (rDNA) quantification and correlations with immune activation.
Ellis CL, Ma ZM, Mann SK, Li CS, Wu J, Knight TH, Yotter T, Hayes TL, Maniar AH, Troia-Cancio PV, Overman HA, Torok NJ, Albanese A, Rutledge JC, Miller CJ, Pollard RB, Asmuth DM. Ellis CL, et al. Among authors: asmuth dm. J Acquir Immune Defic Syndr. 2011 Aug 15;57(5):363-70. doi: 10.1097/QAI.0b013e31821a603c. J Acquir Immune Defic Syndr. 2011. PMID: 21436711 Free PMC article.
Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort Study.
Balagopal A, Asmuth DM, Yang WT, Campbell TB, Gupte N, Smeaton L, Kanyama C, Grinsztejn B, Santos B, Supparatpinyo K, Badal-Faesen S, Lama JR, Lalloo UG, Zulu F, Pawar JS, Riviere C, Kumarasamy N, Hakim J, Li XD, Pollard RB, Semba RD, Thomas DL, Bollinger RC, Gupta A; ACTG PEARLS and NWCS 319 Study team. Balagopal A, et al. Among authors: asmuth dm. J Acquir Immune Defic Syndr. 2015 Oct 1;70(2):163-71. doi: 10.1097/QAI.0000000000000696. J Acquir Immune Defic Syndr. 2015. PMID: 26017661 Free PMC article.
Peginterferon α-2a for the treatment of HIV infection.
Asmuth DM, Utay NS, Pollard RB. Asmuth DM, et al. Expert Opin Investig Drugs. 2016;25(2):249-57. doi: 10.1517/13543784.2016.1132699. Epub 2016 Jan 4. Expert Opin Investig Drugs. 2016. PMID: 26667398 Review.
78 results